Clinical Trials Logo

Clinical Trial Summary

Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication. In hepatitis B infection, cytokines played a vital role. This study was aimed at investigating the changes of cytokines during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to verify whether Peg-IFN-α therapy resulted in the secretion of cytokines.


Clinical Trial Description

Pegylated interferon α-2a(Peg-IFN-α)and Nucleoside analog(ue) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation . In hepatitis B infection, cytokines including Fit-3L, IFN-alpha2, IFN-gama, IL-10, IL-17A,IL-2, IL-6, TNF-alpha, TGF-beta1, TGF-beta2,TGF-beta3, played a vital role.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than nucleoside analog(ue) drugs, which might be related to the increase of cytokine secretion in the case of hepatitis and during Peg-IFN-α therapy.This study was aimed at investigating the changes of cytokines during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to clarify whether Peg-IFN-α therapy led to the secretion of cytokines. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03210506
Study type Interventional
Source Beijing Ditan Hospital
Contact Yao Xie, MD
Phone 8610-84322489
Email xieyao00120184@sina.com
Status Recruiting
Phase N/A
Start date January 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT03329820 - Quality of Life and Health Utility of Patients With CHB Infections N/A
Recruiting NCT04030039 - Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
Recruiting NCT03208998 - The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03210467 - The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03210493 - The Changes of Treg Cells Frequency and Function During Antiviral Therapy N/A
Recruiting NCT03209037 - The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT03209011 - The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy Phase 4
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Recruiting NCT03587467 - Study on Gut Microbiota in Chronic HBV Infected Patients
Completed NCT05355467 - Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum Phase 4
Recruiting NCT04135235 - Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B